Why Orexigen Therapeutics is Falling Today
Orexigen Therapeutics announced today that the regulatory decision for its obesity medication Contrave will be delayed by three months, causing shares to crater in early trading. Are investors overreacting?
Down 18%: Is Orexigen a Bad News Buy?
The stock cratered 18% on a delayed FDA decision...but was the sell-off overdone?
Orexigen's Date With Destiny
Orexigen's Contrave should be approved this week, but will it be able to perform better than obesity drugs from Arena Pharmaceuticals and VIVUS?
As Orexigen Faces FDA Will Weight Loss Landscape Change?
As Orexigen once again faces FDA approval, it appears as though the landscape for weight loss drugs may once again change.